798 Federal Register / Vol. 76, No. 4 / Thursday, January 6, 2011 / Notices 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All nonconfidential 

written submissions will be available for 

public inspection at the Office of the 

Secretary. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of sections 201.10 and 210.50(a)(4) 

of the Commission’s Rules of Practice 

and Procedure (19 CFR 201.10, 

210.50(a)(4)). 

Issued: December 30, 2010. 

By order of the Commission. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 2010–33356 Filed 1–5–11; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation Nos. 731–TA–394–A & 399– 

A (Second Review) (Fourth Remand)] 

Ball Bearings From Japan and the 

United Kingdom 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice of remand proceedings. 

SUMMARY: The U.S. International Trade 

Commission (‘‘Commission’’) hereby 

gives notice of its fourth remand 

proceeding with respect to its 

affirmative determination in the fiveyear review of the antidumping duty 

order on ball bearings from Japan. For 

further information concerning the 

conduct of this proceeding and rules of 

general application, consult the 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A through 

E (19 CFR part 201), and part 207, 

subpart A (19 CFR part 207). 

DATES: Effective Date: December 30, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

James McClure, Office of Investigations, 

telephone 202–205–3191, or David 

Goldfine, Office of General Counsel, 

telephone 202–708–5452, U.S. 

International Trade Commission, 500 E 

Street, SW., Washington, DC 20436. 

Hearing-impaired persons can obtain 

information on this matter by contacting 

the Commission’s TDD terminal on 202– 

205–1810. Persons with mobility 

impairments who will need special 

assistance in gaining access to the 

Commission should contact the Office 

of the Secretary at 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its Internet server (http:// 

www.usitc.gov). 

SUPPLEMENTARY INFORMATION: 

Background.—On December 9, 2010, 

the Court of International Trade (per 

Judge Barzilay) issued an opinion in 

NSK Corp. et al. v. United States, Slip 

Op. 10–133 (‘‘NSK V’’). In that opinion, 

the Court has again affirmed-in-part and 

remanded-in-part the Commission’s 

determinations in Certain Bearings and 

Parts Thereof from Japan and the 

United Kingdom, Inv. Nos. 731–TA– 

394–A & 399–A (Second Review) (Third 

Remand), USITC Pub. 4194 (Aug. 2010). 

In NSK V, the Court affirmed the 

Commission’s determination not to 

cumulate subject imports from the 

United Kingdom because they would 

not likely have a discernible adverse 

impact. NSK V at 4–6. The Court also 

affirmed the Commission’s negative 

determination with respect to the 

United Kingdom. Id. at 6. 

As to the remaining issues with 

respect to the cumulated subject imports 

from France, Germany, Italy, and Japan, 

the Court again affirmed the 

Commission’s findings that the 

cumulated imports would likely have 

significant volume and price effects. Id. 

at 7. Nevertheless, with respect to the 

likely impact by cumulated subject 

imports, the Court again remanded the 

issue to the Commission. Id. at 8–12. 

Under the remand schedule ordered 

by the Court, the Commission was 

required to file a status report with the 

Court on December 20, 2010, advising 

the Court as to whether it would be reopening the record on the likely impact 

issue. The Court also directed the 

parties to submit a proposed joint 

scheduling order for the fourth remand 

proceedings. 

On December 20, 2010, the 

Commission filed the requested status 

report with the Court, advising the 

Court that it will not be re-opening the 

record. On December 20, 2010, the 

parties also submitted a proposed joint 

scheduling order. On December 22, 

2010, the Court approved the proposed 

scheduling order and directed the 

Commission to file its fourth remand 

determination by March 1, 2011. Under 

the remand schedule ordered by the 

Court, Plaintiffs, Plaintiff-Intervenors, 

and Defendant-Intervenors may file 

their comments with the Court 

regarding the Commission’s fourth 

remand determination by April 1, 2011. 

Participation in the proceeding.— 

Only those persons who were interested 

parties to the reviews (i.e., persons 

listed on the Commission Secretary’s 

service list) and parties to the appeal 

may participate in the remand 

proceeding. Such persons need not 

make any additional filings with the 

Commission to participate in the 

remand proceeding, unless they are 

adding new individuals to the list of 

persons entitled to receive business 

proprietary information under 

administrative protective order. 

Business proprietary information (‘‘BPI’’) 

referred to during the remand 

proceeding will be governed, as 

appropriate, by the administrative 

protective order issued in the reviews. 

Written submissions.—The 

Commission is not re-opening the 

record in this remand proceeding. The 

Commission will permit the parties to 

file comments pertaining to the specific 

issues that are the subject of the Court’s 

remand instructions. Comments should 

be limited to no more than fifteen (15) 

double-spaced and single-sided pages of 

textual material. No appendices or other 

attachments are allowed. The parties 

may not themselves submit any new 

factual information in their comments 

and may not address any issue other 

than those that are the subject of the 

Court’s remand instructions. Any such 

comments must be filed with the 

Commission no later than January 14, 

2011. 

All written submissions must conform 

with the provisions of section 201.8 of 

the Commission’s rules; any 

submissions that contain BPI must also 

conform with the requirements of 

sections 201.6, 207.3, and 207.7 of the 

Commission’s rules. The Commission’s 

rules do not authorize filing of 

submissions with the Secretary by 

facsimile or electronic means, except to 

the extent permitted by section 201.8 of 

the Commission’s rules, as amended, 67 

Fed. Reg. 68036 (Nov. 8, 2002). 

In accordance with sections 201.16(c) 

and 207.3 of the Commission’s rules, 

each document filed by a party to the 

investigation must be served on all other 

parties to the investigation (as identified 

by either the public or BPI service list), 

and a certificate of service must be 

timely filed. The Secretary will not 

accept a document for filing without a 

certificate of service. 

Parties are also advised to consult 

with the Commission’s Rules of Practice 

and Procedure, part 201, subparts A 

through E (19 CFR part 201), and part 

207, subpart A (19 CFR part 207) for 

provisions of general applicability 

concerning written submissions to the 

Commission. 

By order of the Commission. 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 76, No. 4 / Thursday, January 6, 2011 / Notices 799 

Issued: December 30, 2010. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 2010–33355 Filed 1–5–11; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 17, 2010, and 

published in the Federal Register on 

June 28, 2010, 75 FR 36680, United 

States Pharmacopeial Convention, 

12601 Twinbrook Parkway, Rockville, 

Maryland 20852, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the following basic 

classes of controlled substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methaqualone (2565) ................... I 

Lysergic acid diethylamide (7315) I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

Codeine-n-oxide (9053) ................ I 

Heroin (9200) ............................... I 

Amphetamine (1100) .................... II 

Drug Schedule 

Methamphetamine (1105) ............ II 

Phenmetrazine (1631) .................. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Phencyclidine (7471) .................... II 

Alphaprodine (9010) ..................... II 

Anileridine (9020) ......................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Drug Schedule 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Drug Schedule 

Sufentanil (9740) .......................... II 

The company plans to import 

reference standards for sale to 

researchers and analytical labs. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

United States Pharmacopeial 

Convention to import the basic classes 

of controlled substances is consistent 

with the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. DEA has 

investigated United States 

Pharmacopeial Convention to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: December 23, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–12 Filed 1–5–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 15, 2010, and 

published in the Federal Register on 

October 26, 2010, 75 FR 65660, 

Noramco Inc., 1440 Olympic Drive, 

Athens, Georgia 30601, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Thebaine (9333) ......................... II 

Tapentadol (9780) ...................... II 

The company plans to import 

Thebaine (9333) analytical reference 

standards for distribution to its 

customers. The company plans to 

import an intermediate form of 

Tapentadol (9780) to bulk manufacture 

Tapentadol for distribution to its 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Noramco Inc. to import the basic classes 

of controlled substances is consistent 

with the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. DEA has 

investigated Noramco Inc. to ensure that 

the company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: December 23, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–11 Filed 1–5–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Publication of Year 2010 Form M–1 

With Electronic Filing Option, Notice 

AGENCY: Employee Benefits Security 

Administration, Department of Labor. 

ACTION: Notice on the Availability of the 

Year 2010 Form M–1 with Electronic 

Filing Option. 

SUMMARY: This document announces the 

availability of the Year 2010 Form M– 

1, Annual Report for Multiple Employer 

Welfare Arrangements and Certain 

Entities Claiming Exception. It is 

generally identical to the 2009 Form M– 

1, except that a few changes were made 

to update the Part 7 compliance 

questions to reflect the current 

provisions of Part 7 that were effective 

in 2010. The Form M–1 may again be 

filed electronically over the Internet. 

FOR FURTHER INFORMATION CONTACT: For 

inquiries regarding the Form M–1 filing 

requirement, contact Amy J. Turner or 

Beth L. Baum, Office of Health Plan 

Standards and Compliance Assistance, 


erowe on DSK5CLS3C1PROD with NOTICES